retatrutide trial results today Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished This week's most cited articles:
Description
Proper storage of compounded semaglutide is critical to maintaining its effectiveness and safety
While these products are often marketed as "wellness" breakthroughs, many have not been assessed for safety, efficacy, or quality, posing severe risks such as hormonal imbalances, liver damage, and infections
Boosts circulation and lymphatic drainage with gua sha
Why? Because it delivers astonishing results at an extremely low cost
Mounting research suggests GLP-1 drugs, which are used to treat diabetes and obesity, may one day help people with alcohol use disorder
